FindTrial
Sign In

Aflibercept 8mg

DRUG6 trials

Sponsors

Kim's Eye Hospital, Edward Wood, MD, Association for Innovation and Biomedical Research on Light and Image, Peking University People's Hospital, Tianjin Medical University Eye Hospital

Conditions

Age-related Macular Degeneration (ARMD)DMEExudative Age-Related Macular DegenerationNeovascular Age-Related Macular Degeneration (nAMD)Neovascular Age-Related Macular Degeneration (nAMD) Wet AMDProliferative Diabetic Retinopathy (PDR)nAMD

Early Phase 1

Biomarkers, Effectiveness, and Safety of Aflibercept 8mg Modified Fixed Dose Regimen in Treatment-Naïve nAMD Patients
Not yet recruitingNCT07728981
Tianjin Medical University Eye HospitalNeovascular Age-Related Macular Degeneration (nAMD) Wet AMD
Start: 2026-07-25End: 2027-12-31Target: 49Updated: 2026-07-27

Phase 4

Switching to Aflibercept 8mg in Patients Showing Limited Response to Previous Treatment
CompletedNCT06683950
Kim's Eye HospitalAge-related Macular Degeneration (ARMD)
Start: 2024-10-21End: 2026-07-14Updated: 2026-07-16
High Dose Eylea for Proliferative Diabetic Retinopathy Outcomes
Active, not recruitingNCT07118670
Edward Wood, MDProliferative Diabetic Retinopathy (PDR)
Start: 2025-12-08End: 2028-04-01Target: 40Updated: 2026-03-18

Unknown Phase

Home Monitoring in eAMD Treatment
Not yet recruitingNCT07340372
Association for Innovation and Biomedical Research on Light and ImageExudative Age-Related Macular Degeneration
Start: 2026-05-01End: 2027-12-01Target: 80Updated: 2026-05-06
Real-world Study of Aflibercept 8 mg in nAMD
RecruitingNCT07640997
Peking University People's HospitalNeovascular Age-Related Macular Degeneration (nAMD)
Start: 2025-11-11End: 2027-12-31Target: 300Updated: 2026-06-11
Real-World Study of Intravitreal Aflibercept 8 mg in Pretreated Eyes With nAMD or DME
Not yet recruitingNCT07761039
Grupo de Estudos da RetinaDME, nAMD
Start: 2026-09-01End: 2027-12-31Target: 100Updated: 2026-08-12